Background: Secukinumab, a fully human antiinterleukin 17A monoclonal antibody, was evaluated in ERASURE and FIXTURE, two phase 3 multicenter double blind vs placebo clinical studies, for efficacy and safety in subjects with moderate to severe plaque psoriasis. Data from these trials provided an opportunity to evaluate the relationship between traditional clinical outcomes and patient-reported symptoms.
Secukinumab in psoriasis
Relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials
Gottlieb, A., Strober, B., Lebwohl, M., Kaufmann, R., Pariser, D., Narbutas, R., Nyirady, J., Zhao, Y., Tran, MH., McLeod, L., Odom, D., & Elewski, B. (2015). Secukinumab in psoriasis: Relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials. Journal of the American Academy of Dermatology, 72(5, Suppl. 1), AB250. https://doi.org/10.1016/j.jaad.2015.02.997